On the technical perspective front, indicators give DVAX a short term outlook of 100% Buy on average. If we dive deeper into the stock’s performance we see the positive picture represented by the PEG ratio, currently standing at 0. The biopharmaceutical company can be reached via phone at 510-848-5100 or via email at [email protected]. Dynavax Technologies Corporation (NASDAQ:DVAX) went up by 17.93% from its latest closing price compared to the recent 1-year high of $12.44. View insider buying and selling activity for Dynavax Technologies or view top insider-selling stocks. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. Dynavax Technologies' stock is owned by a number of retail and institutional investors. Start Your Risk-Free Trial Subscription Here, Ferroglobe Will Get a Big Lift From Demand For Silcon Wafers, Blue Bird Stock is a Dual Tailwinds EV and Re-Opening Play, Nautilus Stock is a Pullback Buying Opportunity Here, The Launch of Truforma Should Send Zomedica to An All-Time High, Defi Markets Pause But New Highs Are In Sight. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Good News For Dynavax Technologies Corporation (NASDAQ:DVAX): Stock Could Rise Another 105.34%. Wall Street analysts have given Dynavax Technologies a "Buy" rating, but there may be better short-term opportunities in the market. The stock has traded between $4.79 and $5.10 so far today. Another comparison is with Bristol-Myers Squibb Company (BMY) whose stock price was down 0% in the last trading session, but has tanked -9.22% over the past year. First Access to Latest . Some companies that are related to Dynavax Technologies include Amgen (AMGN), Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Exact Sciences (EXAS), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Novavax (NVAX), Repligen (RGEN), Neurocrine Biosciences (NBIX) and Ionis Pharmaceuticals (IONS). Shares of Dynavax Technologies (NASDAQ: DVAX) were soaring 18.8% as of 10:50 a.m. EST on Friday. DVAX stock was sold by a variety of institutional investors in the last quarter, including Credit Suisse AG, Victory Capital Management Inc., SG Americas Securities LLC, State of Wisconsin Investment Board, Northern Trust Corp, Alliancebernstein L.P., LPL Financial LLC, and ETF Managers Group LLC. However, this figure declines on the past 10-day timeline to an average of 23.38 Million. Save my name, email, and website in this browser for the next time I comment. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. ET by Tomi Kilgore. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Many investors hope to win big on healthcare stocks as shares can skyrocket when there is good news. The stock has a market capitalization … Dynavax Technologies has received 50.40% “outperform” votes from our community. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Looking for new stock ideas? with 26.67% short float move could be nice. Dynavax Technologies Corporation (NASDAQ:DVAX) price closed higher on Friday, Feb 12, jumping 2.2% above its previous close. Dynavax Technologies Corporatio found using ticker (DVAX) have now 3 analysts in total covering the stock. Dynavax Technologies does not have a long track record of dividend growth. Rating: { {RATING_DATA}} Price *Price Target. Analysts who follow Dynavax Technologies Corporation on average expect it to rise 159.88% over the next twelve months.Those same analysts give the stock an average rating of Strong Buy. Press Release reported 8 hours ago that Dong Yu, Ph.D., Joins Dynavax as Senior Vice President of Vaccine Research Dynavax Technologies Corporation has a research collaboration with Clover Biopharmaceuticals; the University of Queensland and the Coalition for Epidemic Preparedness; and Sinovac Biotech Ltd. for the development of a vaccine candidate to prevent coronavirus (COVID-19). Looking at the stock’s medium term indicators we note that it is averaging as a 100% Buy, while an average of long term indicators are currently assigning the stock as 50% Buy. The stock price of Dynavax Technologies Corporation (NASDAQ: DVAX) increased by over 9% pre-market. What's Happening With Dynavax Technologies Corporation Stock Today? 1y target est: 18.00: All. All in all, Nadeau reiterated an Outperform (i.e. The move came on solid volume too with far more shares changing hands than in a normal session. Support Quality Journalism. Even if you’re not actively in crypto, you deserve to know what’s actually going on... Since then, DVAX stock has increased by 212.1% and is now trading at $9.58. Want to see which stocks are moving? 0. Today ||| 52-Week Range. Their forecasts range from $14.00 to $20.00. Dynavax Technologies Corp (NASDAQ:DVAX) Dynavax Technologies Corp. 8.22. ALSO READ: The Smartest Way to … These Numbers Show Just How Powerful Scopus BioPharma Inc. (NASDAQ:SCPS) Stock Is. Analyst Weighs In, view top-rated stocks among Wall Street analysts, Receive Analysts' Upgrades and Downgrades Daily. Dynavax Technologies Corporation DVAX was a big mover last session, as the company saw its shares rise nearly 7% on the day. Dynavax Technologies Corporation (NASDAQ:DVAX) went up by 3.25% from its latest closing price compared to the recent 1-year high of $12.44. Eddie Gray has an approval rating of 59% among Dynavax Technologies' employees. View institutional ownership trends for Dynavax Technologies. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Learn more. Notably, we see that shares short in January fell slightly given the previous month’s figure stood at 22.85 Million. View all of DVAX's competitors. Dynavax Technologies Corporation (NASDAQ:DVAX) traded at $10.94 at last check on Tuesday, Feb 09, made a downturn move of -2.1% on its previous day’s price. Based on this estimate, we see that current price is roughly 43.74% off the estimated low and 105.34% off the forecast high. Its immuno-oncology portfolio includes development stage products, such as SD-101 and DV281. View the latest Dynavax Technologies Corp. (DVAX) stock price, news, historical charts, analyst ratings and financial information from WSJ. Equity multiplier, or assets relative to shareholders' equity, comes in at 6.54 for Dynavax Technologies Corp; that's greater than it is for 82.46% of US stocks. There were 3 main triggers that sent the stock price up. Given that the stocks previous close was at 5.14 this would imply there is a potential upside of 211.3%. © 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Dynavax Technologies Corp's number of analysts covering the stock is greater than 27.74% of all US stocks. On average, they anticipate Dynavax Technologies' share price to reach $16.33 in the next twelve months. Financially, Dynavax is in a stable cash position, with $129.5 million in the first quarter. Dynavax stock traded up about 5% at $3.48, in a 52-week range of $1.80 to $8.19. Dynavax Technologies Corp. analyst ratings, historical stock prices, earnings estimates & actuals. 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dynavax Technologies in the last year. 4. Collection of curated. ), Dynavax Technologies has received 438 “underperform” votes. 4 analysts have issued 12 month target prices for Dynavax Technologies' stock. Dynavax Technologies Co. (NASDAQ:DVAX) issued its quarterly earnings data on Thursday, February, 25th. Learn about financial terms, types of investments, trading strategies and more. Dynavax Technologies Corporation (NASDAQ:DVAX)’s beta value is holding at 1.41, while the average true range (ATR) indicator is currently reading 0.96. You can opt out at any time. The growth was driven by the news... Vislink Technologies, Inc. ‎(VISL) ‎specializes in designing and manufacturing wireless communications solutions. All rights reserved. The company’s stock price has collected 8.86% of gains in the last five trading sessions. DVAX has a greater average analyst price target than 34.22% of all US stocks. View analysts' price targets for Dynavax Technologies or view top-rated stocks among Wall Street analysts. DVAX Stock Summary. Is it Too Late to Buy Burlington Stores Stock? Click here to get the full story… along with our long list of backdoor Bitcoin strategies. This suggests a possible upside of 70.5% from the stock's current price. According to analysts' consensus price target of $16.33, Dynavax Technologies has a forecasted upside of 70.7% from its current price of $9.57. View today's stock price, news and analysis for Dynavax Technologies Corp. (DVAX). The stock added 91.36% on its value in the past month. The big gain came after the company announced better-than-expected fourth-quarter results after the market close on Thursday. MarketBeat's community ratings are surveys of what our community members think about Dynavax Technologies and other stocks. Dynavax Technologies has a P/B Ratio of 95.70. But the +118.88% upside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher. Click here now. The analysts of H.C. Wainwright & Co. have rated Dynavax Technologies with a Buy rating. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older. Dynavax Technologies Corporation, which has a market valuation of $1.05 Billion, is expected to release its quarterly earnings report on February 25, 2021. The stock price of Dynavax Technologies Corporation (NASDAQ: DVAX) — a biopharmaceutical company focused on developing and commercializing vaccines — increased by 62.76% today as it went from a previous close of $6.31 to $10.27. Counsel and Sec. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.24) by $0.10. Delayed Data. We do not sell or share your information with anyone. It’s free. Get short term trading ideas from the MarketBeat Idea Engine. (Add your “outperform” vote. Dynavax was able to unload SD-101 to TriSalus and in return, will receive an upfront payment, as well as additional milestones and royalties. Looking at the stock we see that its previous close was $11.18 and the beta (5Y monthly) reads 1.37 with the day’s price range being … Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. The consensus price target is $13.67. Get the hottest stocks to trade every day before the market opens 100% free. Shares of DVAX can be purchased through any online brokerage account. Vote “Outperform” if you believe DVAX will outperform the S&P 500 over the long term. The range between the high target price and low target price is between 20 and 14 and has a mean target at 16. Identify stocks that meet your criteria using seven unique stock screeners. According to data from Thomson Reuters, insiders’ percentage holdings are 0.76% of outstanding shares while the percentage share held by institutions stands at 80.86%. $ 0.00. To see all exchange delays and terms of use please see disclaimer. Specifically, 4 analysts have assigned DVAX a recommendation rating as follows: None rate it as a Hold; 4 advise Buy while none analyst(s) assign an Outperform rating. Per this projection, the revenue is forecast to grow +13.7% above that which the company brought in 2020. (Add your “underperform” vote.). For the full year of 2019, the biotech expects net sales to come in at $34 million to $36 million. From this we can glean that short interest is 20.33% of company’s current outstanding shares. View insider buying and selling activity for Dynavax Technologies or or view top insider-buying stocks. Dynavax Technologies' stock was trading at $3.07 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. View Dynavax Technologies' earnings history. Foresight Autonomous company... Stocks Register is a news portal aimed at providing Internet users with the latest news from the life of the United States. Dynavax Technologies employs 231 workers across the globe. It is understandable that investor optimism is growing ahead of the company’s current quarter results. Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Get daily stock ideas top-performing Wall Street analysts. DVAX stock was acquired by a variety of institutional investors in the last quarter, including Avidity Partners Management LP, Chicago Capital LLC, Federated Hermes Inc., Blair William & Co. IL, Panagora Asset Management Inc., Dupont Capital Management Corp, Zurcher Kantonalbank Zurich Cantonalbank, and UBS Asset Management Americas Inc.. Company insiders that have bought Dynavax Technologies stock in the last two years include Andrew A F Hack, and Francis Cano. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Earnings for Dynavax Technologies are expected to grow in the coming year, from ($0.70) to ($0.45) per share. Get the hottest stocks to trade every day before the market opens 100% free. Also, Gilead Sciences Inc (GILD) showed uptrend of 2.2% while its price kept floating at 86.59% over the past year. Is It Time To Get Crazy With El Pollo Loco Stock? Case in point: Dynavax (DVAX) shares shot … Skip to main content. Analysts tracking DVAX have forecast the quarterly EPS to grow by -$0.24 per share this quarter, while the same analysts predict the annual EPS to hit -$0.89 for the year 2021 and up to -$0.17 for 2022. The P/E ratio of Dynavax Technologies is -6.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Receive a free world-class investing education from MarketBeat. 13 employees have rated Dynavax Technologies CEO Eddie Gray on Glassdoor.com. DVAX. On average, analysts have forecast the company’s revenue for the quarter will hit $13.06 Million, with the likely lows of $11.17 Million and highs of $15.22 Million. Dynavax Technologies' mailing address is 2100 Powell Street Suite 900, Emeryville CA, 94608. Press Release reported on 03/01/21 that Dynavax to Present at the H.C. Wainwright Virtual 2021 Global Life Sciences Conference Elsewhere in the market, the S&P 500 Index has rallied 0.47% in last trading session, with the Dow Jones Industrial also saw a positive session on the day with +0.09%. Investors will no doubt be excited to see the share price rise to $15, which is the median consensus price, and at that level DVAX would be +54% from current price. Vote “Underperform” if you believe DVAX will underperform the S&P 500 over the long term. Taking into account the 52-week price action we note that the stock hit a 52-week high of $12.44 and 52-week low of $1.8. The overview shows that DVAX’s price is at present 28.87% off the SMA20 and 62.6% from the SMA50. Dynavax Technologies has received 445 “outperform” votes. You may vote once every thirty days. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. The consensus among Wall Street equities research analysts is that investors should "buy" Dynavax Technologies stock. MarketBeat just released five new trading ideas, but Dynavax Technologies wasn't one of them. Learn more. View which stocks are hot on social media with MarketBeat's trending stocks report. Get Dynavax Technologies alerts: DVAX stock opened at $9.59 on Monday. , 1D Long. Dynavax Technologies has a market capitalization of $1.08 billion and generates $35.22 million in revenue each year. 1.80. HubSpotInc (NYSE: HUBS) – Is There Any Momentum? Motley Fool. Lowest: 12.00 Median: 13.40 Highest: 15.00. Barron's also provides information on historical stock ratings, target … There are currently 4 buy ratings for the stock. Buy) rating on DVAX shares and sticks to a $20 price target. Join now to get the Newsheater.com pre-market morning brief 100% free. Why Dynavax Stock Is Crushing It Today. Dynavax Technologies does not currently pay a dividend. The company’s stock price has collected 14.46% of gains in the last five trading sessions. Jun. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. Top institutional shareholders include Federated Hermes Inc. (10.84%), BlackRock Inc. (7.43%), Chicago Capital LLC (5.25%), Avidity Partners Management LP (3.63%), Blair William & Co. IL (1.98%) and Northern Trust Corp (1.15%). Considering analysts have assigned the stock a price target range of $14-$20 as the low and high respectively, we find the trailing 12-month average consensus price target to be $16.33. Press releases. Dynavax Technologies has a twelve month low of $1.80 and a twelve month high of $12.44. Our Accessibility Statement The average estimate suggests sales growth for the quarter will likely rise by 23.6% when compared to those recorded in the same quarter in the last financial year. Fundamental company data provided by Zacks Investment Research. Dynavax Technologies' management team includes the following people: Chief Medical Officer & Sr. VP of Clinical Devel., Medical and Regulatory Affairs, Principal Accounting Officer & Controller, VP of Investor Relations & Corp. Communications. In general, analysts have rated the stock Buy, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares. Dynavax Technologies has only been the subject of 2 research reports in the past 90 days. News. An analysis of the Dynavax Technologies Corporation (NASDAQ:DVAX) stock in terms of its daily trading volume indicates that the 3-month average is 5.29 Million. The consensus rating is ‘Buy’. Dynavax Technologies has received a consensus rating of Buy. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Export data to Excel for your own analysis. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. Latest Analyst Research & Price Targets for Dynavax Technologies (DVAX-Q). Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. Based on aggregate information from My MarketBeat watchlists, some companies that other Dynavax Technologies investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (bmrn), (MDVN) (MDVN), Incyte (incy), Sorrento Therapeutics (SRNE), Vaxart (VXRT), Matinas BioPharma (MTNB), First Solar (FSLR), Inovio Pharmaceuticals (INO) and ADMA Biologics (ADMA). Every day the website publishes the latest news of the business, technologies, politics, economy, culture, sports and the most interesting events in the world. Dynavax Technologies is headquartered at 2100 Powell Street Suite 900, Emeryville CA, 94608. Dynavax Technologies has a consensus rating of Buy and a consensus price target of $14.63. dvax price at support. You have entered an incorrect email address! Staying with the analyst view, there is a consensus estimate of $40.06 Million for the company’s annual revenue in 2021. The company’s 5Y monthly beta was ticking 1.41 while its P/E ratio in the trailing 12-month period read 0. As for Dynavax Technologies Corporation, the P/E ratio stands at 0 lower than that of Amgen Inc’s at 19.26 and Bristol-Myers Squibb Company’s 0. Today’s Change. In the past three months, Dynavax Technologies insiders have sold more of their company's stock than they have bought. One share of DVAX stock can currently be purchased for approximately $9.58. looks like its getting ready for a move up. High institutional ownership can be a signal of strong market trust in this company. Analyst. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. Dynavax started at outperform with $14 stock price target at Evercore ISI. The company stock has a Forward Dividend ratio of 0, while the dividend yield is 0. The price target was set to $ 15.00. Only 13.33% of the stock of Dynavax Technologies is held by insiders. The stats also highlight that short interest as of January 28, 2021, stood at 22.4 Million shares, which puts the short ratio at the time at 6.62. As of Mar 05. This figure suggests upside of a handsome 112%. See Dynavax Technologies Corporatio (DVAX) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. Investment News. Chief Ethics & Compliance Officer, Sr. VP, Gen. Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX.". MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. It also develops and sells microwave communications machinery utilizing coded orthogonal frequency... FSRX recently turned 9% lower as profit-takers stepped in after the stock made big gains this week on successful trial results. What To Make Of Poshmark’s First Earnings Report. This stock, which remained volatile and traded within the range of $4.84 –$7.92 in the past one-month time frame, witnessed a sharp increase on Friday. View analyst ratings for Dynavax Technologies or view top-rated stocks. View our full suite of financial calendars and market data tables, all for free. Dynavax Technologies Corporation has partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to create a vaccine against COVID-19 infection; a collaboration with Valneva SE to initiate a vaccine program for the coronavirus, COVID-19; and collaboration with Medicago to develop a novel adjuvanted COVID 19 vaccine candidate. Company insiders that have sold Dynavax Technologies company stock in the last year include Justin Burgess, and Robert Janssen. Dynavax Technologies is scheduled to release its next quarterly earnings announcement on Thursday, May 6th 2021. Click here now. The company has a quick ratio of 3.47, a current ratio of 4.35 and a debt-to-equity ratio of 2.59. The indicator jumps to 13.8% when calculated based on the past 30 days. This is why it happened. Sign-up to receive the latest news and ratings for DVAX and its competitors with MarketBeat's FREE daily newsletter. Based on analysts offering 12 month price targets for DVAX in the last 3 months. A look at the daily price movement shows that the last close reads $9.53, with intraday deals fluctuated between $9.33 and $10.05. The official website for Dynavax Technologies is www.dynavax.com. None analyst(s) have tagged the Dynavax Technologies Corporation (DVAX) stock as Underperform, with none recommending Sell. This puts Eddie Gray in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. View which stocks have been most impacted by COVID-19. The stock price of Dynavax Technologies Corporation (NASDAQ: DVAX) – a biopharmaceutical company focused on developing and commercializing novel vaccines – increased by over 9% pre-market as of 8:13 AM ET. In turn, Dynavax has been bleeding money of late. Clean Energy Fuels Corp. (CLNE) rose 15% in Wednesday's trade to $13.59 despite a weak quarterly report. With a price/sales ratio of 20.61, Dynavax Technologies Corp has a higher such ratio than 90.79% of stocks in our set. Start your free 7-Day Trial. 100% Free, Get The Best Stocks To Trade Every Day!...100% Free. In this case, analysts estimate an annual EPS growth of -0.59% for the year and -0.81% for the next year. Bullish Prospects For Star Bulk Carriers Corp. (NASDAQ:SBLK) Shares In 2021, ON Semiconductor Corporation (NASDAQ:ON) down -2.32%: This is what analysts are now forecasting, Thinking of Buying Ulta Beauty, Inc. (NASDAQ:ULTA) Stock? Turning out attention to how the Dynavax Technologies Corporation stock has performed in comparison to its peers in the industry, here’s what we find: DVAX’s stock is +2.2% on the day and +86.59% in the past 12 months, while Amgen Inc (AMGN) traded +0.92% in the last session and was positioned +6.35% up on its price 12 months ago. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 65.01, with weekly volatility standing at 11.2%. Data is currently not available. Earnings Preview for Dynavax Technologies, Dynavax’s Hepatitis B Vaccine Authorized In Europe; Shares Rise 6%, Dynavax Announces European Commission Marketing Authorization for HEPLISAV B®, a 2 Dose Adult Hepatitis B Adjuvanted Vaccine, Dynavax to Present at the Cowen 41st Annual Health Care Conference, Moving Average Crossover Alert: Dynavax (DVAX), Dynavax to Report Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call on February 25, 2021, Dong Yu, Ph.D., Joins Dynavax as Senior Vice President of Vaccine Research, Dynavax, Serum Institute Start Phase 1 Trial For Tdap Booster Vaccine, Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), Dynavax and Serum Institute of India Announce First Participant Dosed in a Phase 1 Clinical Trial Evaluating an Improved Tdap Vaccine Adjuvanted with CpG 1018, Is Dynavax Stock Still Worth Buying After Its 60%-Plus Rally? That average rating earns the stock an Analyst Ranking of 80, which means it ranks higher than 80 of stocks, based on data compiled by InvestorsObserver. Company insiders that own Dynavax Technologies stock include Andrew A F Hack, Francis Cano, Justin Burgess, Robert Coffman and Robert Janssen. Dynavax Technologies Corporation (NASDAQ:DVAX)’s beta value is holding at 1.41, while the average true range (ATR) indicator is currently reading 0.96. The upside potential (average analyst target price relative to current price) of DVAX is higher than 86.4% of all US stocks. The biopharmaceutical company earns $-152,600,000.00 in net income (profit) each year or ($1.87) on an earnings per share basis. 80.02% of the stock of Dynavax Technologies is held by institutions. Do Not Sell My Information. Volume today is below average. View Price Target for DVAX Access over 100 stock metrics like Beta, EV/EBITDA, PE10, Free Cash Flow Yield, KZ Index and Cash Conversion Cycle. Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Here’s What You Need to Know, Here’s Why CLNE Stock Mounted 15% Despite Poor Quarterly Report: Clean Energy Fuels (CLNE), Will Vislink Technologies Inc. (VISL) be successful in remaining Competitive, Foresight Autonomous Holdings ADR (FRSX) Giving Back Gains Made on Successful Trial News. Stock analysis for Dynavax Technologies Corp (DVAX:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. -0.25 / -2.95%. View our earnings forecast for Dynavax Technologies. So far 1,823,373 shares have traded compared to average … MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Considering analysts have assigned the stock a price target range of $14-$20 as the low and high respectively, we find the trailing 12-month average consensus price target to be $16.33. See what's happening in the market right now with MarketBeat's real-time news feed.
Weekly Garbage Pickup Near Me, Langdale Care Home Email, How To Improve Reproducibility Of An Experiment, I Moist Soap Uses In Telugu, Evod Twist 2 Vv Battery 1600mah, Cobalt Boats Kansas Citybest Hair Diffuser, Rlftf Stock Price,